MiR-223 enhances the anti-tumor effect of doxorubicin and cisplatin in TNBCSCs.

<p>(A) MDA-MB-231 CSCs and MDA-MB-435 CSCs were transfected with miR-223 mimics and HAX-1 vector. Twenty-four hours after transfection, the cells were treated with doxorubicin (2 μg/ml) for 48 h. Relative cell viability was determined by MTT assay. *<i>P</i><0.05 <i>vs</i>. the doxorubicin+miR-NC group, t test, ^#<i>P</i><0.05 <i>vs</i>. the doxorubicin+miR-223 group, t test. (B) MDA-MB-231 CSCs and MDA-MB-435 CSCs were transfected with miR-223 mimics and HAX-1 vector. Twenty-four hours after transfection, the cells were treated with cisplatin (2 μM) for 48 h. Relative cell viability was determined by MTT assay. *<i>P</i><0.05 <i>vs</i>. the cisplatin+miR-NC group, t test, ^#<i>P</i><0.05 <i>vs</i>. the cisplatin+miR-223 group, t test.